XTL begins patient dosing in phase 1 trial of XTL-2125 to treat hepatitis C

By E. Janene Geiss

Philadelphia, May 4 - XTL Biopharmaceuticals Ltd. announced Thursday the start of patient dosing in a phase 1 clinical trial of XTL-2125 for the treatment of chronic hepatitis C.

The phase 1 trial is a placebo-controlled, randomized, dose-escalating study that will evaluate the safety, tolerability and antiviral activity of single and multiple doses of XTL-2125, according to a company news release.

The study will enroll 48 patients into six cohorts comprised of eight patients each, of which two are placebo patients. Each patient will receive a single dose, followed by a 14-day multi-dosing regimen beginning one week after the single dose administration, officials said.

XTL-2125 is an oral non-nucleoside hepatitis C virus polymerase inhibitor. In preclinical studies, XTL-2125 has demonstrated robust activity against the hepatitis C virus in both cell-based and in-vivo systems, officials said.

In addition, XTL-2125 has demonstrated a good safety profile in multiple animal species.

"XTLbio is in the unique position of having two novel compounds - XTL-2125 and XTL-6865 - in clinical trials in patients with chronic hepatitis C," Ron Bentsur, chief executive officer, said in the release.

XTL is a New York City biopharmaceutical company engaged in acquisition, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.